Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy
- PMID: 14613994
Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy
Abstract
Purpose: Midkine (MK) is a member of a family of heparin-binding growth factors, which was reported to have an important role in angiogenesis. Although MK was reported to be associated with bladder cancer progression, the functional significance of MK expression in bladder cancer progression has not been elucidated. The objectives of this study were to determine whether overexpression of MK in bladder cancer cells enhances their malignant potential and to evaluate the inhibitory effect of the antiangiogenic agent TNP-470 on the growth of MK-overexpressing bladder cancer cells in vivo.
Experimental design: We introduced the MK gene into human bladder cancer UM-UC-3 cells that do not secrete a detectable level of MK protein and generated the MK-overexpressing cell line UM-UC-3/MK. The biological activity of secreted MK was evaluated using a human umbilical vein endothelial cell proliferation assay. To investigate the in vivo effects of MK overexpression on tumor growth, each cell line was injected s.c. and orthotopically into nude mice. To evaluate the therapeutic effects of the antiangiogenic agent, mice were given TNP-470 after s.c. injection of each cell line. The microvessel density of tumors was quantitated by immunohistochemistry of CD31.
Results: The heparin affinity-purified conditioned media of UM-UC-3/MK cells significantly enhanced human umbilical vein endothelial cell proliferation. MK expression had no effect on in vitro growth but conferred a growth advantage on both s.c. and orthotopic tumors in vivo. Furthermore, enhanced tumor growth was closely associated with increased microvessel density. Significant inhibition of tumor growth by TNP-470 treatment was observed only in UM-UC-3/MK tumors and not in control tumors.
Conclusions: We demonstrated that overexpression of the MK gene causes an increase in the angiogenic activity of cells through vascular endothelial cell growth, resulting in enhanced malignant potential of human bladder cancer cells. Moreover, the present findings suggest that TNP-470 could be used as a novel therapeutic adjunct to conventional agents for patients with advanced bladder cancer overexpressing MK.
Similar articles
-
Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.Clin Cancer Res. 2002 Jul;8(7):2389-98. Clin Cancer Res. 2002. PMID: 12114444
-
Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts.Clin Cancer Res. 2000 Mar;6(3):971-8. Clin Cancer Res. 2000. PMID: 10741723
-
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.Clin Cancer Res. 2003 Feb;9(2):886-99. Clin Cancer Res. 2003. PMID: 12576464
-
Antiangiogenic strategies in neuroblastoma.Cancer Treat Rev. 2005 Feb;31(1):27-34. doi: 10.1016/j.ctrv.2004.09.006. Epub 2004 Nov 18. Cancer Treat Rev. 2005. PMID: 15707702 Review.
-
The role of growth factors, angiogenic enzymes and apoptosis in neovascularization and tumor growth-collected publications.Verh K Acad Geneeskd Belg. 2002;64(3):197-224. Verh K Acad Geneeskd Belg. 2002. PMID: 12238243 Review.
Cited by
-
Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma.Br J Cancer. 2013 May 14;108(9):1854-61. doi: 10.1038/bjc.2013.157. Epub 2013 Apr 16. Br J Cancer. 2013. PMID: 23591195 Free PMC article.
-
Midkine Mediates Intercellular Crosstalk between Drug-Resistant and Drug-Sensitive Neuroblastoma Cells In Vitro and In Vivo.ISRN Oncol. 2013 Sep 3;2013:518637. doi: 10.1155/2013/518637. eCollection 2013. ISRN Oncol. 2013. PMID: 24083030 Free PMC article.
-
Midkine Controls Arteriogenesis by Regulating the Bioavailability of Vascular Endothelial Growth Factor A and the Expression of Nitric Oxide Synthase 1 and 3.EBioMedicine. 2018 Jan;27:237-246. doi: 10.1016/j.ebiom.2017.11.020. Epub 2017 Nov 26. EBioMedicine. 2018. PMID: 29233575 Free PMC article.
-
Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus.Oncotarget. 2017 Jun 20;8(25):40181-40189. doi: 10.18632/oncotarget.13658. Oncotarget. 2017. PMID: 27903979 Free PMC article.
-
Midkine in inflammation.ScientificWorldJournal. 2011;11:2491-505. doi: 10.1100/2011/517152. Epub 2011 Dec 27. ScientificWorldJournal. 2011. PMID: 22235180 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical